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1. Introduction 
The binding of various ubstrates of the microsomal 
mono-oxygenase ystem to its terminal oxidase, cyt- 
chrome P450, is associated with characteristic absorb- 
ance changes in the difference spectrum of the micro- 
somes [l-3] . Thus, hexobarbital, aminopyrine, 
testosterone and laurate, as well as a number of other 
substances, elicit spectral changes characterized by a 
trough in the 420 nm region and a peak in the 390 
nm region when added to a suspension of rat liver 
microsomes. This spectral change has been termed 
type I. The type II spectral change, on the other hand, 
has a peak at about 430 mn and trough at 390-400 
nm and is likewise produced by a variety of substances, 
among them aniline. 
In a recent paper we have suggested that the com- 
petitive ’ :‘-?i;n that certain drugs, steroids and fat- 
ty acids exert on each other’s oxidative metabolism in 
the liver microsomes may be related to the competi- 
tion for binding to a common cytochrome P-450 
species [4]. The substances u ed in that study, hex- 
obarbital, aminopyrine, testosterone and laurate, were 
all potent inducers of type I spectra. However, it was 
not possible to decide whether all of these substrates 
may interact at a common or at different site(s) of 
the cytochrome P-450 molecule. 
Furthermore, aminopyrine and hexobarbital, though 
slowly metabolized by guinea-pig adrenal microsomes, 
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do not elicit detectable spectral changes in the diffe- 
rence spectrum of these particles [5] . That a binding 
of these drugs to adrenal microsomes might indeed 
take place was suggested by our recent fmding that 
they interfere with the type I spectral change produced 
by cortisol [5] , but it was not possible to decide wheth- 
er or not the drugs and the steroids interacted at a com- 
mon site on the cytochrome P-450 molecule. 
The present’investigation was designed to study 
in further detail the interaction between these sub- 
strates in their binding to cytochrome P-450 of rat 
liver and guinea-pig adrenal microsomes. 
2. Materials and methods 
Male Sprague-Dawley rats (ca. 200 g) and albino 
guinea-pigs (400-500 g) of local strain were used. 
The animals were starved overnight and killed by a 
blow on the head and decapitated. Rat liver and 
guinea-pig adrenal microsomes were isolated ac- 
cording to the procedure for liver microsomes des- 
cribed by Ernster et al. [6] . The microsomal pellets 
were rinsed with ice-cold 0.25 M sucrose solution and 
resuspended in this medium at a protein concentra- 
tion of 10 me/ml. protein was measured by the meth- 
od of Lowry et al. [7]. 
The sum of the absorbance changes at the wave- 
lengths of the peak and trough of the type I spectral 
change caused by the addition of hexobarbital to liver 
microsomes was recorded at 390 nm minus 420 nm 
in a phoenix Dual-Wavelength Scanning Spectropho- 
tometer. The magnitude of the spectral change in- 
duced by the addition of cortisol-21-sodium succinate 
249 
Volume 6, number 3 FEBS LEmERS February 1970 
(cortisol succinate) to adrenal microsomes was meas- 
ured at 385 mn minus 420 mn. The cuvette contained, 
in a final volume of 3 ml, liver or adrenal microsomes 
(3.5-5.6 mg protein), 50 mM tris Cl pH 5 and 15 
mM KCl. I- 10 ~1 of aqueous olutions of hexobarbi- 
tal70 mM) or cortisol succinate (20 mM) were added 
stepwise (in 1 ~1 aliquots) and the change in absorb- 
ance recorded. The procedure was then repeated in the 
presence of various concentrations of other compounds 
previously shown to interfere with the type I spectral 
change induced by hexobarbital in liver microsomes 
(aminopyrine, testosterone and laurate [4]), or by cor- 
tisol succinate in adrenal nlicrosomes (hexobarbital 
[51X 
The data obtained were treated as in the classical 
enzyme-substrate-inhibitor m dels, using the absorb- 
ance change in place of initial velocity, as recently 
suggested by Leibman et al. [8]. 
All chemicals employed were standard commercial 
products. 
Table 1 
Concentrations of substances required for half-maximal spec- 
tral changes (Ks) when added to suspensions of liver micro- 
somes. 
Substance KS* 
OIM) 
Maximal absorbance 
(AOWo-42o/3 ml/ 
5.6 mg protein) 
Hexobarbital 50 0.031 
Aminopyrine 133 0.017 
Testosterone 8 0.019 
Laurate 4 0.023 
* The KS values were derived from double reciprocal plots of 
the sum of the absorbance changes at the wavelengths of the 
peak (390 nm) and trough (420 mn) associated with the ad- 
dition of increasing concentrations of the respective sub- 
stances to suspensions of rat liver microsomes. 
3. Results 
Hexobarbital, aminopyrine, testosterone and lau- 
rate all induce type I spectral changes when added to 
a suspension of rat liver microsomes. The binding af- 
finities for testosterone and laurate were considerably 
higher than those for hexobarbital and aminopyrine, 
as revealed by the K, values presented in the table. It 
may be interesting to note the low KS value obtained 
with laurate (4 PM) which is in good agreement with 
the previously reported Km value of 6 PM for the o- 
oxidation of laurate catalyzed by rat liver microsomes 
[9] . A similarity between KS and K,,, has also previous- 
ly been observed for hexobarbital and aminopyrine, 
and it has been proposed that the two constants re- 
flect the binding of the substrate to the enzyme [3]. 
In a previous investigation [4] , we observed that 
aminopyrine, testosterone and laurate interfere with 
the type I spectral change induced in rat liver micro- 
somes by hexobarbital. This finding was taken to in- 
dicate that all four substances may actually bind to 
the same cytochrome P-450 species. This phenomenon 
was now studied in further detail. 
The spectral change licited by the addition of in- 
creasing amounts of hexobarbital to rat liver micro- 
somes was measured in the absence and presence of 
various concentrations of aminopyrine. Data in fg 1 
reveal that aminopyrine acts as a competitive inhibitor 
of the spectral change produced by the addition of 
hexobarbital, i.e. the apparent KS for hexobarbital is 
increased in the presence of aminopyrine. Similar 
results were obtained when the titration of the spec- 
tral change with hexobarbital was performed in the 
presence of’testosterone or laurate at various concen- 
trations (figs. 2 and 3). 
With adrenal microsomes the situation appears to 
be somewhat different. Titration of the type I spec- 
tral change by the addition of increasing concentra- 
tions of cortisol succinate rendered an apparent KS 
value of 0.25 mM (fig. 4). In the presence of hexo- 
barbital the spectral change induced by cortisol suc- 
cinate was markedly inhibited. However, this inhibi- 
tion was not competitive, but rather seemed to be of 
a mixed type. 
4. Comments 
The evidence available suggests hat a number of 
substances undergoing hydroxylation in liver micro- 
somes, such as certain drugs, steroids and fatty acids, 
interact with a common cytochrome P-450 species. 
The competitive inhibition that these substrates ex- 
ert on each other’s metabolism ay thus be explained 
by a competition for their binding to the cytochrome. 
Although the mechanism of the binding underlying 
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Fig. 1. Effect of aminopyrine on the type I spectral change induced by hexobarbital in rat liver microsomes. 
10 20 
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Fig. 2. Effect of testosterone on the type I spectral change induced by hexobarbital in rat liver microsomes. 
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Fig. 3. Effect of laurate on the type I spectral change induced by hexobarbital in rat liver microsomes. 
seems reasonable to assume that the substrates inter- 
act with the protein moiety which, in turn, gives rise 
to altered absorption characteristics of the heme [lo] . 
It seems probable that the type I spectral change is a 
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Fig. 4. Effect of hexobarbital on the type I spectral change in- 
duced by cortisol succinate in guinea-pig adrenal microsomes. 
the type I spectral change is not yet elucidated, it
reflection of the site on the protein with which the 
various ubstrates interact rather than an inherent at- 
tribute of the substrate molecule as such. Thus, testos- 
terone gives rise to a type I spectral change when ad- 
ded to rat liver microsomes, whereas the same com- 
pound induces a type II spectral change with kidney 
cortex microsomes from the same species [111. Fur- 
thermore, cortisol elicits a type I spectral change in 
guinea-pig liver microsomes but a type II spectrum in 
microsomes from rat liver [S] . Leibman et al. [8] 
have recently reported that barbiturates which elicit 
type I spectral changes in rat liver microsomes com- 
petitively inhibit each other’s binding to cytochrome 
P-450. However, they postulated that this may be the 
case only when the substrates studied are structurally 
related, a conclusion which is not supported by the 
present data. Our observation that aminopyrine, testos- 
terone and laurate act as competitive inhibitors of 
the type I spectral change induced by hexobarbital in 
rat liver microsomes adds further support for the ex- 
istence of a common binding sites for these substrates 
on the liver-microsomal cytochrome P-450. 
Although hexobarbital does not elicit detectable 
spectral changes with guinea-pig adrenal microsomes, 
it can bind to these particles, as revealed by its inter- 
ference with the cortisol-induced type I spectral change 
[5] . In this case, however, the inhibition was not com- 
petitive. The present results are thus compatible with 
the hypothesis that structural differences exist between 
the cytochrome P-450 molecules of liver and adrenal 
microsomes, possibly in the form of different regula- 
tory subunits, and that such differences may in fact 
be responsible for their different catalytic functions. 
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